Biomarker testing, treatment patterns and outcomes in previously treated pMMR or non-MSI-H metastatic colorectal cancer patients.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-05-15 DOI:10.1080/14796694.2025.2504246

K Desai, M Amonkar, R Jain, G Patton, K Estenson, A Sartaj, D Cosgrove, S Sura

{"title":"Biomarker testing, treatment patterns and outcomes in previously treated pMMR or non-MSI-H metastatic colorectal cancer patients.","authors":"K Desai, M Amonkar, R Jain, G Patton, K Estenson, A Sartaj, D Cosgrove, S Sura","doi":"10.1080/14796694.2025.2504246","DOIUrl":null,"url":null,"abstract":"Aim: To assess biomarker testing utilization, treatment patterns, and clinical outcomes in previously treated proficient mismatch repair deficient (pMMR) or non-microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) patients.Materials & methods: Using the iKnowMed electronic health record database, this study included pMMR/non-MSI-H adult mCRC patients previously treated with standard-of-care (SoC) chemotherapies between 1 January 2016 and 31 December 2021. Patients were censored for overall survival (OS) and real-world progression-free survival (rwPFS) at their last visit date or the end of study period, 31 August 2022.Results: MSI/MMR testing was conducted in 70.9% of mCRC patients. In 292 previously treated mCRC patients, 69.5% received SACT (regorafenib:14.8%, trifluridine+tipiracil (TAS-102):12.3%, other SACT:72.9%), 28.8% received BSC and 1.7% received no BSC/SACT. The most common other SACT included irinotecan- (37.4%) and oxaliplatin-based (14.8%) therapies. The most patients were tested for KRAS (89%) and BRAF (81%). Overall, the median (95% CI) OS and rwPFS was 7.4(5.8,8.8) and 3.5(3.2,4.3) months, respectively.Conclusions: Only 70.9% of mCRC patients received guideline-recommended MSI/MMR testing, indicating a need for improved testing rates. Additionally, only 27.1% of previously treated mCRC patients received SoC options (regorafenib/TAS-102). The real-world variability in treatment choices and a high rate of chemotherapy rechallenge in subsequent lines highlight an unmet need in this patient population.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2504246","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To assess biomarker testing utilization, treatment patterns, and clinical outcomes in previously treated proficient mismatch repair deficient (pMMR) or non-microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) patients.

Materials & methods: Using the iKnowMed electronic health record database, this study included pMMR/non-MSI-H adult mCRC patients previously treated with standard-of-care (SoC) chemotherapies between 1 January 2016 and 31 December 2021. Patients were censored for overall survival (OS) and real-world progression-free survival (rwPFS) at their last visit date or the end of study period, 31 August 2022.

Results: MSI/MMR testing was conducted in 70.9% of mCRC patients. In 292 previously treated mCRC patients, 69.5% received SACT (regorafenib:14.8%, trifluridine+tipiracil (TAS-102):12.3%, other SACT:72.9%), 28.8% received BSC and 1.7% received no BSC/SACT. The most common other SACT included irinotecan- (37.4%) and oxaliplatin-based (14.8%) therapies. The most patients were tested for KRAS (89%) and BRAF (81%). Overall, the median (95% CI) OS and rwPFS was 7.4(5.8,8.8) and 3.5(3.2,4.3) months, respectively.

Conclusions: Only 70.9% of mCRC patients received guideline-recommended MSI/MMR testing, indicating a need for improved testing rates. Additionally, only 27.1% of previously treated mCRC patients received SoC options (regorafenib/TAS-102). The real-world variability in treatment choices and a high rate of chemotherapy rechallenge in subsequent lines highlight an unmet need in this patient population.

查看原文本刊更多论文

pMMR或非msi - h转移性结直肠癌患者的生物标志物检测、治疗模式和结果

目的：评估先前治疗过的熟练错配修复缺陷（pMMR）或非微卫星不稳定性高（MSI-H）转移性结直肠癌（mCRC）患者的生物标志物检测使用、治疗模式和临床结果。材料和方法：使用iKnowMed电子健康记录数据库，本研究纳入了2016年1月1日至2021年12月31日期间曾接受标准护理（SoC）化疗的pMMR/非msi - h成年mCRC患者。在最后一次访问日期或研究期结束时（2022年8月31日），对患者的总生存期（OS）和真实世界无进展生存期（rwPFS）进行审查。结果：70.9%的mCRC患者进行了MSI/MMR检测。在292例既往治疗的mCRC患者中，69.5%接受了SACT（瑞非尼：14.8%，三氟定+替吡拉西（TAS-102）：12.3%，其他SACT:72.9%）， 28.8%接受了BSC， 1.7%未接受BSC/SACT。最常见的其他SACT包括伊立替康（37.4%）和奥沙利铂（14.8%）治疗。大多数患者接受KRAS（89%）和BRAF（81%）检测。总体而言，中位（95% CI） OS和rwPFS分别为7.4（5.8,8.8）和3.5（3.2,4.3）个月。结论：只有70.9%的mCRC患者接受了指南推荐的MSI/MMR检测，表明需要提高检测率。此外，只有27.1%的既往治疗过的mCRC患者接受了SoC选择（regorafenib/TAS-102）。现实世界中治疗选择的可变性和后续产品线中化疗再挑战的高比率突出了这一患者群体的未满足需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.